ELEVEN BIOTHERAPEUTICS, INC. (NASDAQ:EBIO) Files An 8-K Other Events

ELEVEN BIOTHERAPEUTICS, INC. (NASDAQ:EBIO) Files An 8-K Other Events
Item 8.01 – Other Events.

Story continues below

On April 3, 2018, Eleven Biotherapeutics, Inc. (the “Company”) issued a press release announcing that preliminary efficacy and safety data from the Company’s ongoing Phase 3 VISTA trial of Vicinium™ in patients with non-muscle invasive bladder cancer who have been previously treated with bacillus Calmette-Guérin have been selected for presentation during a plenary session at the American Urological Association Annual Meeting. The plenary session is currently scheduled for May 21, 2018 at 11:00 a.m. PT.

A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits.


Eleven Biotherapeutics, Inc. Exhibit
EX-99.1 2 ebio-auaabstractv20180402f.htm EXHIBIT 99.1 Exhibit Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to be Presented in a Plenary Session at American Urological Association Annual MeetingEleven Biotherapeutics to Host Conference Call in Conjunction with Data Presentation in MayCAMBRIDGE,…
To view the full exhibit click here

About ELEVEN BIOTHERAPEUTICS, INC. (NASDAQ:EBIO)

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).

An ad to help with our costs